1-6 of 6
Richard L. Piekarz
Close
Sort by
Journal Articles

MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor

Arup R. Chakraborty, Robert W. Robey, Victoria L. Luchenko, Zhirong Zhan, Richard L. Piekarz, Jean-Pierre Gillet, Andrew V. Kossenkov, Julia Wilkerson, Louise C. Showe, Michael M. Gottesman, Nathan L. Collie, Susan E. Bates
Journal: Blood
Blood (2013) 121 (20): 4115–4125.
https://doi.org/10.1182/blood-2012-08-449140
Published: 2013
Includes: Supplemental data
Journal Articles

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

Clinical Trials & Observations
Richard L. Piekarz, Robin Frye, H. Miles Prince, Mark H. Kirschbaum, Jasmine Zain, Steven L. Allen, Elaine S. Jaffe, Alexander Ling, Maria Turner, Cody J. Peer, William D. Figg, Seth M. Steinberg, Sonali Smith, David Joske, Ian Lewis, Laura Hutchins, Michael Craig, A. Tito Fojo, John J. Wright, Susan E. Bates
Journal: Blood
Blood (2011) 117 (22): 5827–5834.
https://doi.org/10.1182/blood-2010-10-312603
Published: 2011
Journal Articles

Phase II Trial of Romidepsin, FK228, in Cutaneous and Peripheral T-Cell Lymphoma: Clinical Activity and Molecular Markers.

Richard L. Piekarz, MD PhD, Robin Frye, RN, Maria Turner, MD, John Wright, MD, PhD, Steven Allen, MD, Mark H. Kirschbaum, MD, Jasmine Zain, MD, Miles Prince, MD, Laura Hutchins, MD, Louise C. Showe, PhD, William D. Figg, PharmD, Tito Fojo, MD, PhD, Susan E. Bates, MD, for All Collaborators
Journal: Blood
Blood (2006) 108 (11): 2469.
https://doi.org/10.1182/blood.V108.11.2469.2469
Published: 2006
Journal Articles

Completion of the First Cohort of Patients with Cutaneous T-Cell Lymphoma Enrolled on a Phase II Trial of Depsipeptide.

Richard L. Piekarz, MD, PhD, Robin Frye, RN, Maria Turner, MD, John Wright, MD, PhD, Steven Allen, MD, Mark H. Kirschbaum, MD, Jasmine Zain, MD, Miles Prince, MD, Susan E. Bates, MD, for All Collaborators
Journal: Blood
Blood (2005) 106 (11): 231.
https://doi.org/10.1182/blood.V106.11.231.231
Published: 2005
Journal Articles

T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance

Richard L. Piekarz, Robert W. Robey, Zhirong Zhan, Ganesh Kayastha, Anousheh Sayah, Amina H. Abdeldaim, Sonia Torrico, Susan E. Bates
Journal: Blood
Blood (2004) 103 (12): 4636–4643.
https://doi.org/10.1182/blood-2003-09-3068
Published: 2004
Journal Articles

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report

Brief Report
Richard L. Piekarz, Rob Robey, Victor Sandor, Susan Bakke, Wyndham H. Wilson, Laila Dahmoush, Douglas M. Kingma, Maria L. Turner, Rosemary Altemus, Susan E. Bates
Journal: Blood
Blood (2001) 98 (9): 2865–2868.
https://doi.org/10.1182/blood.V98.9.2865
Published: 2001